- Home
- XBIT vs IFRX Comparison
XBIT vs IFRX Comparison
Compare XBIT & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XBIT | IFRX |
|---|---|---|
| Founded | 2005 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.3M | 60.6M |
| IPO Year | 2015 | 2017 |
Fundamental Metrics
Financial Performance| Metric | XBIT | IFRX |
|---|---|---|
| Price | $2.41 | $0.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 37.6K | ★ 242.8K |
| Earning Date | 03-13-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,054.36 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.09 | $0.71 |
| 52 Week High | $3.62 | $1.94 |
Technical Indicators
Market Signals| Indicator | XBIT | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.01 | 49.25 |
| Support Level | $2.32 | $0.77 |
| Resistance Level | $2.49 | $1.16 |
| Average True Range (ATR) | 0.10 | 0.08 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 75.94 | 47.91 |
Price Performance
Historical ComparisonAbout XBIT XBiotech Inc.
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.